Cargando…

Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52

INTRODUCTION: Improvements in both musculoskeletal and non-musculoskeletal manifestations are important treatment goals in psoriatic arthritis (PsA). OBJECTIVE: These post hoc analyses determined whether additional benefits related to various PsA domains are observed in patients simultaneously achie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Behrens, Frank, Leage, Soyi Liu, Sapin, Christophe, Baou, Celine El, De La Torre, Inmaculada, Meszaros, Gabriella, Schett, Georg, Combe, Bernard, van den Bosch, Filip, Gossec, Laure
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599337/ https://www.ncbi.nlm.nih.gov/pubmed/34515902 http://dx.doi.org/10.1007/s10067-021-05891-5

Ejemplares similares

Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H
por: Kristensen, Lars-Erik, et al.
Publicado: (2021)

Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
por: Smolen, Josef S., et al.
Publicado: (2020)

Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial
por: Reich, Kristian, et al.
Publicado: (2022)

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
por: Smolen, Josef S, et al.
Publicado: (2020)

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
por: Deodhar, Atul, et al.
Publicado: (2023)

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2020)

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
por: Genovese, Mark C, et al.
Publicado: (2018)

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies
por: Combe, Bernard, et al.
Publicado: (2021)

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
por: Gottlieb, Alice B, et al.
Publicado: (2018)

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study
por: Östör, Andrew, et al.
Publicado: (2022)

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
por: Mease, Philip J, et al.
Publicado: (2020)

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
por: Kristensen, Lars Erik, et al.
Publicado: (2022)

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
por: Landewé, Robert B M, et al.
Publicado: (2023)

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
por: Cai, Lin, et al.
Publicado: (2021)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
por: Coates, Laura C., et al.
Publicado: (2022)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
por: Ritchlin, Christopher T, et al.
Publicado: (2023)

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
por: Coates, Laura C., et al.
Publicado: (2022)

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
por: Landewé, Robert BM, et al.
Publicado: (2021)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
por: McGonagle, Dennis, et al.
Publicado: (2023)

52 Procedures in 52 Weeks: An Innovative Curriculum for Emergency Medicine Residents
por: Walsh, Ryan, et al.
Publicado: (2017)

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2020)

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2021)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

The Hospital Spirit in Torquay: Mr. H. J. Packe on the Progress of the Torbay Hospital
Publicado: (1912)

PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
por: Siebert, Stefan, et al.
Publicado: (2022)

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Enthesitis in psoriatic arthritis (Part 1): pathophysiology
por: Araujo, Elizabeth G, et al.
Publicado: (2020)

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
por: Gossec, Laure, et al.
Publicado: (2020)

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study
por: Mease, Philip, et al.
Publicado: (2020)

Spirits
Publicado: (1882)

Spirits
Publicado: (1880)

Spirits
Publicado: (1878)

Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2017)

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
por: Mease, Philip J, et al.
Publicado: (2021)

Creative 52: weekly projects to invigorate your photography portfolio
por: Adler, Lindsay
Publicado: (2014)

DNA methylation changes in infants between 6 and 52 weeks
por: Wikenius, Ellen, et al.
Publicado: (2019)

The spirit of Gambo
por: Hume, Tobias, d. 1645
Publicado: (1996)

Phenomenology of spirit
por: Hegel, Georg Wilhelm Friedrich
Publicado: (1977)

Cannot write session to /tmp/vufind_sessions/sess_3vtarja47tpsf7ti2336j4dqjb